 Helicobacter pylori
"Helicobacter pylori" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A spiral bacterium active as a human gastric pathogen. It is a gram-negative, urease-positive, curved or slightly spiral organism initially isolated in 1982 from patients with lesions of gastritis or peptic ulcers in Western Australia. Helicobacter pylori was originally classified in the genus CAMPYLOBACTER, but RNA sequencing, cellular fatty acid profiles, growth patterns, and other taxonomic characteristics indicate that the micro-organism should be included in the genus HELICOBACTER. It has been officially transferred to Helicobacter gen. nov. (see Int J Syst Bacteriol 1989 Oct;39(4):297-405).
| Descriptor ID |
D016480
|
| MeSH Number(s) |
B03.440.500.550 B03.660.150.280.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Helicobacter pylori".
Below are MeSH descriptors whose meaning is more specific than "Helicobacter pylori".
This graph shows the total number of publications written about "Helicobacter pylori" by people in UAMS Profiles by year, and whether "Helicobacter pylori" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2025 | 1 | 1 | 2 | | 2024 | 1 | 0 | 1 | | 2023 | 2 | 0 | 2 | | 2022 | 2 | 0 | 2 | | 2021 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 | | 2019 | 3 | 0 | 3 | | 2018 | 1 | 1 | 2 | | 2017 | 1 | 1 | 2 | | 2016 | 3 | 0 | 3 | | 2015 | 2 | 0 | 2 | | 2014 | 3 | 1 | 4 | | 2013 | 2 | 0 | 2 | | 2012 | 3 | 0 | 3 | | 2011 | 4 | 1 | 5 | | 2010 | 3 | 2 | 5 | | 2009 | 2 | 1 | 3 | | 2008 | 4 | 1 | 5 | | 2007 | 2 | 0 | 2 | | 2005 | 6 | 0 | 6 | | 2004 | 4 | 1 | 5 | | 2003 | 2 | 0 | 2 | | 2002 | 1 | 0 | 1 | | 2001 | 3 | 0 | 3 | | 2000 | 1 | 0 | 1 | | 1992 | 1 | 0 | 1 | | 1991 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Helicobacter pylori" by people in Profiles over the past ten years.
-
Camargo MC, Abnet CC, Davis JL, Monge C, Lam TK, Gopal S, Young M, Daschner P, Wallace TA, Rodr?guez LM, Castle PE, Umar A, Richmond E. A summary of the National Cancer Institute Think Tank on Advancing Gastric Cancer Prevention. J Natl Cancer Inst. 2025 Nov 01; 117(11):2169-2174.
-
Wu PJ, Tsay FW, Wu DC, Yang JC, Chuah SK, Chen KY, Chen CL, Lee CL, Shih CA, Liu YH, Shiu SI, Tai WC, Kuo CH, Lei WY, Kao SS, Tsai TJ, Feng IC, Koseki M, Hsu PI, Sheu MJ. Sequential changes of antibiotic resistances of Helicobacter pylori in Taiwan from 2019 to 2024. World J Gastroenterol. 2025 Oct 21; 31(39):111380.
-
Edhi A, Gangwani MK, Aziz M, Jaber F, Khan Z, Inamdar S, Thrift AP, Desai TK. Helicobacter pylori infection does not influence the progression from gastroesophageal reflux disease to Barrett's esophagus to esophageal adenocarcinoma. Minerva Gastroenterol (Torino). 2024 Dec; 70(4):454-462.
-
Lin CH, Hsu PI, Tseng CD, Chao PJ, Wu IT, Ghose S, Shih CA, Lee SH, Ren JH, Shie CB, Lee TF. Application of artificial intelligence in endoscopic image analysis for the diagnosis of a gastric cancer pathogen-Helicobacter pylori infection. Sci Rep. 2023 08 17; 13(1):13380.
-
Hsu PI, Chen KY, Tai WC, Yang JC, Tsay FW, Liu YH, Chen CL, Lee CL, Yeh HZ, Kuo CH, Chuah SK, Lee HC, Shie CB, Shiu SI, Kao JY, Yamaoka Y, Graham DY, Wu DC. Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial. Am J Gastroenterol. 2023 07 01; 118(7):1184-1195.
-
Chuah YY, Wu DC, Chuah SK, Chen KY, Yang JC, Lee CL, Chen CL, Shiu SI, Shie CB, Shih CA, Tsay FW, Liu YH, Hsu PI. REAP-HP survey 2020: Comparing the real-world practice and expectation in Helicobacter pylori eradication of the Taiwanese gastroenterologists in 2015 and 2020. Helicobacter. 2022 Dec; 27(6):e12931.
-
Dabo B, Pelucchi C, Rota M, Jain H, Bertuccio P, Bonzi R, Palli D, Ferraroni M, Zhang ZF, Sanchez-Anguiano A, Thi-Hai Pham Y, Thi-Du Tran C, Gia Pham A, Yu GP, Nguyen TC, Muscat J, Tsugane S, Hidaka A, Hamada GS, Zaridze D, Maximovitch D, Kogevinas M, Fern?ndez de Larrea N, Boccia S, Pastorino R, Kurtz RC, Lagiou A, Lagiou P, Vioque J, Camargo MC, Paula Curado M, Lunet N, Boffetta P, Negri E, La Vecchia C, Luu HN. The association between diabetes and gastric cancer: results from the Stomach Cancer Pooling Project Consortium. Eur J Cancer Prev. 2022 05 01; 31(3):260-269.
-
Hsu PI, Tsay FW, Kao JY, Peng NJ, Chen YH, Tang SY, Kuo CH, Kao SS, Wang HM, Wu IT, Shie CB, Chuah SK, Wu DC. Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection. Helicobacter. 2021 Oct; 26(5):e12840.
-
Chang YL, Tung YC, Tu YK, Yeh HZ, Yang JC, Hsu PI, Kim SE, Wu MF, Liou WS, Shiu SI. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis. BMJ Open Gastroenterol. 2020 09; 7(1).
-
Lyons K, Le LC, Pham YT, Borron C, Park JY, Tran CTD, Tran TV, Tran HT, Vu KT, Do CD, Pelucchi C, La Vecchia C, Zgibor J, Boffetta P, Luu HN. Gastric cancer: epidemiology, biology, and prevention: a mini review. Eur J Cancer Prev. 2019 09; 28(5):397-412.
-
Li J, Wu G, Fu Q, Ge H, Liu S, Li X, Cheng B. Exploring the influence of conserved lysine69 on the catalytic activity of the helicobacter pylori shikimate dehydrogenase: A combined QM/MM and MD simulations. Comput Biol Chem. 2019 Dec; 83:107098.
-
Hsu PI, Pan CY, Kao JY, Tsay FW, Peng NJ, Kao SS, Chen YH, Tsai TJ, Wu DC, Tsai KW. Short-term and long-term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota. J Gastroenterol Hepatol. 2019 Nov; 34(11):1968-1976.
-
Cheng HC, Liou JM, Luo JC, Chiu CT, Wu MS, Lee YC, Wu CY, Wu DC, Hsu PI, Chang CC, Chang WL, Lin JT, Sheu BS. The implementation of the consensus on the management of Helicobacter pylori and barriers to consensus. Helicobacter. 2018 Oct; 23(5):e12533.
-
Hsu PI, Pan CY, Kao JY, Tsay FW, Peng NJ, Kao SS, Wang HM, Tsai TJ, Wu DC, Chen CL, Tsai KW. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria. Helicobacter. 2018 Aug; 23(4):e12498.
-
Thorell K, Bengtsson-Palme J, Liu OH, Palacios Gonzales RV, Nookaew I, Rabeneck L, Paszat L, Graham DY, Nielsen J, Lundin SB, Sj?ling ?. In Vivo Analysis of the Viable Microbiota and Helicobacter pylori Transcriptome in Gastric Infection and Early Stages of Carcinogenesis. Infect Immun. 2017 10; 85(10).
-
Ikoma N, Badgwell BD, Mansfield PF. Multimodality Treatment of Gastric Lymphoma. Surg Clin North Am. 2017 Apr; 97(2):405-420.
-
Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone CA, Fischbach L, Bazzoli F, Gisbert JP. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2016 Jun 28; (6):CD009034.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|